Economic Impact of Bimekizumab for Psoriatic Arthritis and Axial Spondyloarthritis in France

Speaker(s)

De Pouvourville G1, Fabre E2, Schleret T2, Leproust S3, Chabani B4, Lyris N5, Willems D6, McCarthy P7, Goupille P8
1ESSEC, Paris, Ile de France, France, 2UCB Pharma, Colombes, France, 3IQVIA, Courbevoie, France, 4IQVIA, Paris, 75, France, 5UCB Pharma, Slough, UK, 6UCB Pharma, Brussels, Belgium, 7REMAP, Cheshire, UK, 8CHU de Tours, Tours, France

Presentation Documents

OBJECTIVES: This study aimed to assess the budget impact (BI) of the introduction of bimekizumab, a humanised monoclonal immunoglobulin (Ig)-G1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, as a treatment option for patients diagnosed with Psoriatic Arthritis (PsA) or Axial Spondyloarthritis (axSpA) in France.

METHODS: A BI model with a 5-year time horizon was developed to estimate the economic impact of introducing bimekizumab into the therapeutic strategy from the French payer perspective. The budget impact analysis included all relevant comparators (anti-tumor necrosis factor (TNF)-alpha, anti-IL, and Janus kinase inhibitors (JAKi)) in both indications. Direct medical costs were considered, including treatment acquisition (list prices), administration, monitoring, and costs associated with adverse events (AE). The main market share uptake assumption was a gain of bimekizumab over anti-IL-17 and anti-IL-23 treatments.

Clinical data were obtained from published network meta-analyses (for the probability of response using the American College of Rheumatology score - ACR50 for PsA and the Assessment of SpondyloArthritis International Society score - ASAS40 for axSpA) and clinical trials (for the incidence of AE). Target populations assessed by the French Health Authority (HAS) were considered. Outcomes included incremental and cumulated costs, and budget impact.

RESULTS: In the eligible population of 20,050 patients (12,250 patients with PsA and 7,800 patients with axSpA), the introduction of bimekizumab resulted in total cost savings of €6,098,564 over the 5-year time horizon, corresponding to a 0.97% decrease of the overall budget of €631,722,498. Savings were mainly driven by treatment acquisition cost (99,97%).

CONCLUSIONS: Based on this budget impact analysis, the introduction of bimekizumab to the PsA and axSpA markets in France is expected to have a neutral impact on the overall French health insurance budget over a 5-year time horizon.

Code

EE234

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis

Disease

Drugs, Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal)